Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces
Aspergillus fumigatus
in Cystic Fibrosis
Am J Respir Crit Care Med
.
2024 Nov 1;210(9):1155-1158.
doi: 10.1164/rccm.202406-1128RL.
Authors
Sarah J Morgan
1
,
David P Nichols
2
,
Windy Ni
1
,
Gina Hong
3
,
Stephen J Salipante
4
,
George M Solomon
5
,
Steven M Rowe
2
5
,
John P Clancy
3
,
Robert A Cramer
6
,
Pradeep K Singh
1
Affiliations
1
Departments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
2
Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
3
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
4
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
5
Department of Medicine, University of Alabama, Birmingham, Alabama, USA; and.
6
Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine , Hanover, New Hampshire, USA.
PMID:
39189854
DOI:
10.1164/rccm.202406-1128RL
No abstract available
Publication types
Letter
Grants and funding
SINGH19R0/Cystic Fibrosis Foundation/United States
STANTO19R0/Cystic Fibrosis Foundation/United States
DK089507/HL/NHLBI NIH HHS/United States
DK117469/HL/NHLBI NIH HHS/United States
R01HL148274/HL/NHLBI NIH HHS/United States